Medical Policy Update for February 6, 2024
Medical Guidelines | Reason for Update |
|---|---|
| BCR-ABL 1 Testing AHS – M2027 | Reviewed by Avalon 3rd Quarter 2023 CAB. Policy archived. Criteria moved to new policy AHS - M2182 Genomic Testing for Hematopoietic Neoplasms. |
| Genetic Testing for Acute Myeloid Leukemia AHS – M2062 | Reviewed by Avalon 3rd Quarter 2023 CAB. Policy archived. Criteria moved to new policy AHS - M2182 Genomic Testing for Hematopoietic Neoplasms. |
| Genomic Testing for Hematopoietic Neoplasms AHS - M2182 (PDF) | New policy developed. Clinical information and criteria from M2027 BCR-ABL1 Testing and M2062 Genetic Testing for Acute Myeloid Leukemia moved to this new policy. Includes most recent NCCN guidelines. Medical Director review 10/2023. Notification given 12/5/2023 for effective date 2/6/2024. |
| Medical Necessity (PDF) | Definition of Medical Necessity updated for clarity to align with North Carolina G.S. 58-50-61. Medical Director Review 2/2024. |
| Progesterone Therapy in High Risk Pregnancies | Policy reviewed by Medical Director 1/2024. No change to policy statement. Policy archived. |
Blue Cross and Blue Shield of North Carolina does not discriminate on the basis of race, color, national origin, sex, age or disability in its health programs and activities. Learn more about our non-discrimination policy and no-cost services available to you.
Information in other languages: Español 中文 Tiếng Việt 한국어 Français العَرَبِيَّة Hmoob ру́сский Tagalog ગુજરાતી ភាសាខ្មែរ Deutsch हिन्दी ລາວ 日本語
© 2024 Blue Cross and Blue Shield of North Carolina. ®, SM Marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield plans. All other marks and names are property of their respective owners. Blue Cross and Blue Shield of North Carolina is an independent licensee of the Blue Cross and Blue Shield Association.